Bullish indicating open at $55-$60, IPO prices at $37
AUDUBON, Pa. - Globus Medical, Inc. (NYSE:GMED), a musculoskeletal technology company with a market capitalization of $7.63 billion and maintaining a "GREAT" financial health score according to InvestingPro, announced Monday that Keith Pfeil has been appointed President and Chief Executive Officer, effective July 18, 2025, replacing Daniel Scavilla who resigned to pursue another opportunity.
Pfeil, who joined Globus in 2019 as Senior Vice President and Chief Financial Officer, was promoted to Executive Vice President, Chief Operating Officer and Chief Financial Officer in 2024. The company also appointed Kyle Kline, previously Senior Vice President of Finance, as the new Chief Financial Officer.
"Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization," said David C. Paul, Globus Medical Founder and Executive Chairman, in a press release.
The musculoskeletal technology company also released preliminary second quarter 2025 sales results, reporting expected revenue of approximately $745.3 million, an 18.4% increase compared to the same period last year. Base business sales, excluding the recently acquired Nevro, Inc., are anticipated to be around $650.8 million, representing a 3.3% increase over Q2 2024. The company maintains a robust gross profit margin of 67% and is currently trading near its 52-week low, with InvestingPro analysis suggesting the stock is undervalued at its current price of $56.34.
Pfeil noted that the company’s U.S. Spine business grew approximately 7.4% on a day-adjusted basis compared to the prior year quarter, delivering its highest quarterly revenue since the 2023 merger with NuVasive.
Globus Medical reaffirmed its full-year 2025 guidance, projecting revenue between $2.80 billion and $2.90 billion, with non-GAAP fully diluted earnings per share expected to range from $3.00 to $3.30.
The company will announce complete financial results for the second quarter on August 7, 2025, after market close. Get deeper insights into Globus Medical’s performance with InvestingPro, which offers exclusive access to 10+ additional ProTips and comprehensive financial analysis through the Pro Research Report, helping investors make informed decisions ahead of earnings.
In other recent news, Globus Medical reported its first-quarter results for 2025, which revealed unexpected revenue and earnings shortfalls. These shortfalls were primarily due to lower sales of Enabling Technology products and supply chain issues related to integrating legacy products from the NuVasive merger. Despite these challenges, JMP analysts noted the company’s strong demand for its Enabling Tech segment and maintained a Market Perform rating. Meanwhile, BTIG downgraded Globus Medical from Buy to Neutral, expressing concerns about the company’s ability to meet growth targets in its Spine business. Piper Sandler, however, maintained an Overweight rating, suggesting that while the Nevro acquisition may negatively impact financial results in the short term, the company remains a high-quality franchise.
In a strategic move, Globus Medical announced a $500 million stock buyback, emphasizing a commitment to long-term shareholder value. The buyback decision reflects a belief in a disconnect between the company’s intrinsic value and market valuation, according to CFO Keith Pfeil. Additionally, Globus Medical expanded its navigation capabilities with the introduction of the DuraPro oscillating system and the launch of Verzera, a navigated high-speed drill system. These developments aim to enhance procedural workflows in spine surgery and target a $550 million high-speed drill market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.